https://www.selleckchem.com/pr....oducts/glx351322.htm
Our work implicates miR-181a/362/382/19a and PTEN as potential biomarkers and targets for novel prognostic, diagnostic, and therapeutic strategies targeting HBV-related HCC. The approval of immune checkpoint inhibitors (ICI) for metastatic melanoma in 2011 has changed the treatment landscape of this disease. However, current trend of the population-based survival remains unclear. 8078 patients with metastatic melanoma diagnosed in the pre-ICI (2005-201 and post-ICI period (2011-2016) were enrolled from the Surveillance, Epidemiology
Like
Comment
Share
